$81.61
3.06% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US45337C1027
Symbol
INCY

Incyte Stock price

$81.61
+11.63 16.62% 1M
+12.56 18.19% 6M
+12.54 18.16% YTD
+20.49 33.52% 1Y
+7.62 10.30% 3Y
-12.61 13.38% 5Y
-25.67 23.93% 10Y
+74.37 1,027.21% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+2.42 3.06%
ISIN
US45337C1027
Symbol
INCY
Industry

Key metrics

Basic
Market capitalization
$15.5b
Enterprise Value
$13.1b
Net debt
positive
Cash
$2.4b
Shares outstanding
194.1m
Valuation (TTM | estimate)
P/E
18.1 | 13.4
P/S
3.4 | 3.2
EV/Sales
2.9 | 2.7
EV/FCF
13.7
P/B
3.7
Financial Health
Equity Ratio
63.3%
Return on Equity
1.0%
ROCE
21.9%
ROIC
63.0%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$4.6b | $4.8b
EBITDA
$1.0b | $1.6b
EBIT
$994.5m | $1.5b
Net Income
$870.9m | $1.1b
Free Cash Flow
$958.1m
Growth (TTM | estimate)
Revenue
18.9% | 13.5%
EBITDA
1,057.5% | 1,104.5%
EBIT
1,425.1% | 1,262.4%
Net Income
794.8% | 3,418.3%
Free Cash Flow
793.6%
Margin (TTM | estimate)
Gross
93.4%
EBITDA
22.2% | 33.8%
EBIT
21.7%
Net
19.0% | 23.8%
Free Cash Flow
20.9%
More
EPS
$4.4
FCF per Share
$4.9
Short interest
5.2%
Employees
3k
Rev per Employee
$1.6m
Show more

Is Incyte a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Incyte Stock Analysis

Unlock Scores for Free

Analyst Opinions

34 Analysts have issued a Incyte forecast:

18x Buy
53%
15x Hold
44%
1x Sell
3%

Analyst Opinions

34 Analysts have issued a Incyte forecast:

Buy
53%
Hold
44%
Sell
3%

Financial data from Incyte

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
4,585 4,585
19% 19%
100%
- Direct Costs 302 302
24% 24%
7%
4,283 4,283
19% 19%
93%
- Selling and Administrative Expenses 1,293 1,293
13% 13%
28%
- Research and Development Expense 1,971 1,971
17% 17%
43%
1,019 1,019
1,058% 1,058%
22%
- Depreciation and Amortization 24 24
6% 6%
1%
EBIT (Operating Income) EBIT 995 995
1,425% 1,425%
22%
Net Profit 871 871
795% 795%
19%

In millions USD.

Don't miss a Thing! We will send you all news about Incyte directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Incyte Stock News

Neutral
Business Wire
7 days ago
WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Departure of Chief Financial Officer Christiana Stamoulis.
Neutral
GlobeNewsWire
12 days ago
MONTREAL, July 31, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a supplemental application to ANVISA, the Brazilian health regulatory agency, seeking approval for an additional indication for MINJUVI® (tafasitamab) in combination...
Neutral
Seeking Alpha
14 days ago
Incyte Corporation (NASDAQ:INCY ) Q2 2025 Earnings Conference Call July 29, 2025 8:00 AM ET Company Participants Christiana Stamoulis - Executive VP & CFO Greg Shertzer - Senior Director of Investor Relations Mohamed Issa - Executive Vice President & Head of U.S. Oncology Pablo J. Cagnoni - President and Head of Research & Development William Meury - CEO, President & Director Conference Call Pa...
More Incyte News

Company Profile

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Head office United States
CEO Herve Hoppenot
Employees 2,617
Founded 1991
Website www.incyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today